Masimo price target raised to $206 from $178 at BTIG

BTIG analyst Marie Thibault raised the firm’s price target on Masimo (MASI) to $206 from $178 and keeps a Buy rating on the shares after its Q4 earnings beat. The company is moving quickly with its margin expansion plans, having already increased its FY25 Healthcare operating margin guidance from 26% in November to at least 26.5% in January and now 27.5-28.0%, which reflects continued cost structure optimization efforts and prioritizing certain R&D initiatives with the highest ROI, the analyst tells investors in a research note. Masimo has many levers available to enable continued long-term margin expansion in the outyears, the firm adds.